-
Mashup Score: 0Adakveo - European Medicines Agency - 2 year(s) ago
Adakveo
Source: European Medicines AgencyCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 9Jaypirca: Pending EC decision - European Medicines Agency - 2 year(s) ago
Jaypirca: Pending EC decision
Source: European Medicines AgencyCategories: Hem/Oncs, Latest HeadlinesTweet-
Important #MCL news: Jaypirca - #Pirtobrutinib - given positive opinion for R/R MCL in Europe! Indication: R/R MCL including prior cov BTKi (broader indication than FDA which is 3rd line+) European Medicines Agency https://t.co/uI7PrUyQWV via @EMA_News https://t.co/ClHtq8dHcM https://t.co/Ptsnspo4Nb
-
-
Mashup Score: 1Sotyktu: Pending EC decision - European Medicines Agency - 2 year(s) ago
Sotyktu: Pending EC decision
Source: European Medicines AgencyCategories: Healthcare Professionals, Latest HeadlinesTweet-
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua
-
-
Mashup Score: 4Meeting highlights from the Committee for Medicinal Products Human Use (CHMP) 20 - 23 February 2023 European Medicines Agency - 2 year(s) ago
Meeting highlights from the Committee for Medicinal Products Human Use (CHMP) 20 – 23 February 2023
Source: European Medicines AgencyCategories: Hem/Oncs, Latest HeadlinesTweet-
CHMP recommends naraparib/abi for 1st line CRPC with BRCA1/2 mutations only, based on MAGNITUDE, but this had a wider HRR biomarker panel (ATM, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2). Are these just passengers?⬆️ momentum for BRCA for PARPi in CRPC https://t.co/ZjbyXDxo27
-
EMA’s human medicines committee (CHMP) recommended granting a marketing authorisation for Akeega (niraparib/abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer with BRCA 1/BRCA 2 mutations. https://t.co/Sx0rLWLUPK
-
-
Mashup Score: 2Lagevrio: Pending EC decision - European Medicines Agency - 2 year(s) ago
Lagevrio: Pending EC decision
Source: European Medicines AgencyCategories: Healthcare Professionals, Latest HeadlinesTweet-
EMA rejects molnupiravir from $mrk. “Based on the totality of data, it was not possible to conclude that Lagevrio can reduce the risk of hospitalisation or death or shorten the duration of illness or time to recovery in adults at risk of severe disease.” https://t.co/zq5jstWMMz
-
-
Mashup Score: 0Trogarzo - European Medicines Agency - 2 year(s) ago
Trogarzo
Source: European Medicines AgencyCategories: Infectious Disease, Latest HeadlinesTweet-
Whoa! Ibalizumab withdrawn from EU entirely....great commitment to ppl w limited hiv treatment options from @Theratech_ @tristanjbarber, Brian west @EATGx & I met them last year & were assured access would be supported...utter crap #trogarzo @GerettiAnna https://t.co/soSU7FG7MA https://t.co/PMiumH3oqj
-
-
Mashup Score: 2Tecvayli - European Medicines Agency - 2 year(s) ago
Tecvayli
Source: European Medicines AgencyCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨 CORRECTION: After a helpful tip from Janssen, I found this helpful gem on page 90 of the EMA's assessment report: Teclistamab is a modified IgG lambda mAb, not kappa, and how it affects SIFE is not yet fully characterized. More mysteries to solve! https://t.co/IuYCODt4dX https://t.co/0ntjBPmaLF https://t.co/TAzHpXrNUX
-
🚨 CORRECTION: After a helpful tip from Janssen, I found this helpful gem on page 90 of the EMA's assessment report: Teclistamab is a modified IgG lambda mAb, not kappa, and how it affects SIFE is not yet fully characterized. More mysteries to solve! https://t.co/IuYCODt4dX https://t.co/dQ1DlTGSJr
-
-
Mashup Score: 3Hemlibra: Pending EC decision - European Medicines Agency - 2 year(s) ago
Hemlibra: Pending EC decision
Source: European Medicines AgencyCategories: Hem/Oncs, Latest HeadlinesTweet-
2nd important decision of the day. The CHMP have given a positive response for the use of emicizumab in moderate #hemophilia A. Within 67 days the European Commission is likely to approve this drug for this indication. https://t.co/B82gYfIcWp 1/2
-
-
Mashup Score: 2
First gene therapy to treat haemophilia B
Source: European Medicines AgencyCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @EMA_News: The #CHMP recommended for authorisation the 1⃣st gene therapy to treat #haemophilia B in adults ⬇️ https://t.co/yM6LFvMMa3
-
-
Mashup Score: 14Mounjaro - European Medicines Agency - 2 year(s) ago
Mounjaro
Source: European Medicines AgencyCategories: Cardiologists, Latest HeadlinesTweet-
RT @CristobMorales: https://t.co/fgaMLahz18 ⚠️⚠️MOUNJARO:This medicine is authorised for use in the European Union 🇪🇺 @EMA_News y Ficha Téc…
-
Noticia triste para las personas con #drepanocitosis. El comité asesor de la EMA recomienda, en base a los resultados del estudio fase 3, revocar la autorización a #crizanlizumab, el anti P-selectina aprobado condicionalmente con los resultados del fase 2 https://t.co/Ft4sgy2EuZ